2025 has marked a turning point in Alzheimer’s disease research and care, with significant advances in early diagnosis, prevention, and treatments. These developments, already beginning to impact clinical practice, confirm a direction in which Ace Alzheimer Center Barcelona has been working for years: anticipating the disease and placing science at the service of people
Early Diagnosis: Blood Biomarkers Become Consolidated
One of the most notable developments in 2025 has been the progress of plasma biomarkers as tools supporting Alzheimer’s diagnosis. New blood tests, based on proteins such as pTau217 or pTau181, make it possible to identify or rule out brain pathology associated with the disease in a less invasive and more accessible way.
This progress validates a key strategic line at Ace, which has long promoted early detection through biomarkers, genetics, and longitudinal cohorts. During 2025, Ace professionals presented new results at international conferences, such as the Alzheimer’s Association International Conference (AAIC), thereby strengthening the knowledge needed to move toward increasingly precise and personalized diagnoses.
Prevention: Intervening Before Symptoms Appear
Research published in 2025 has also reinforced the value of multidomain interventions in people at risk of cognitive decline. Programs combining physical activity, nutrition, cognitive stimulation, and cardiovascular risk factor control have demonstrated improvements in cognitive function.
This approach fully aligns with Ace’s vision, which integrates prevention and early intervention as a fundamental part of Alzheimer’s care. Working before symptoms appear is key to delaying disease progression and preserving quality of life.
Treatments: Innovation with Impact on Daily Life
2025 has also brought developments in disease-modifying treatments, including more convenient new administration methods that reduce the care burden for patients and families. These advances open up new opportunities but also require clear clinical criteria, well-defined care pathways, and appropriate healthcare planning.
In this context, Ace has played an active role in scientific and clinical reflection in Europe. Through the HUB Alzheimer Barcelona, with Ace’s participation, position statements have been promoted to ensure the responsible and equitable implementation of new treatments, always placing safety and patient benefit at the center.
Applied Innovation: Technology and Person-Centered Care
Beyond the headlines, 2025 has been a key year for bringing innovation closer to everyday life. Ace has continued promoting projects that integrate technology, cognitive stimulation, and personalization. Digital health programs aimed at people with mild cognitive impairment or in the early stages of dementia.
These initiatives reflect Ace’s commitment to a person-centered care model that also recognizes the fundamental role of families and caregivers.
Looking Ahead
The 2025 balance confirms that Alzheimer’s is entering a new stage, where earlier diagnosis, better prevention, and the application of innovation based on solid clinical criteria are essential. Many of the advances achieved this year consolidate a way of working that is part of Ace’s DNA.
At Ace Alzheimer Center Barcelona, we will continue working to transform scientific knowledge into real benefits for people, today and in the future.
